Full-Time

Quality Assurance Specialist

Posted on 5/11/2026

Abzena

Abzena

201-500 employees

CDMO for complex biologics and ADCs

Compensation Overview

$90k - $125k/yr

San Diego, CA, USA

In Person

Category
QA & Testing (1)
Requirements
  • Minimum of B.S. degree in Life Sciences or Engineering with 4+ years of experience in a GMP regulated Biopharmaceutical facility or equivalent
  • Demonstrated proficiency of technical operations in the manufacturing / engineering space and ability to drive quality improvements within the organization
  • Experience with driving lean projects and principles within an organization to drive continuous improvements
  • Experience in batch record review, quality records and disposition activities
  • Knowledge of industry standards and regulation requirements for biologics and parenteral products in clinical development and commercial
  • Knowledge of GMP regulations, good documentation practices, cGMP, 21CFR, USP and other applicable regulations, standards, and guidance
  • Ability to work in a cross-functional environment and resilience to a fast-paced environment
  • Ability to manage a team and ensure development of respective associates
Responsibilities
  • Act as BPO for the Batch Disposition process at Abzena San Diego.
  • This includes ownership of the overall Disposition process, support on the creation of Disposition Packets, and the ability to work cross functionally with other departments to obtain the required key deliverables.
  • This individual will need to work with the Project Management Organization (PMO) and partner with clients to ensure all requirements are met and information is cascaded accordingly.
  • Support the Quality Control (QC) Organization in laboratory data, protocol and report review, provide and support implementation of QC CAPAs, and support QC on Out of Specification (OOS) and Over Action Limit (OAL) quality events.
  • Support the disposition of Bulk Drug Substance, Bulk Intermediate, Research Cell Banks (RCB) and Master Cell Banks (MCB) and Working Cell Banks (WCB) to enable forward processing in manufacturing.
  • Be the primary point of contact for engineering and facilities for quality related actions.
  • Be an SME of batch record review and disposition of buffers / media manufactured by Abzena.
  • Support client batch record review processes and aid in the responses to client findings.
  • Support Operations groups in initiation, investigation and approval of Deviations, Change Controls, CAPAs, ILIs and OOSs as applicable.
  • Support Operations groups in the review and approval of Standard Operating Procedures (SOPs), Master Batch Records (MBRs), Quality Control Protocols and Reports, etc.
  • Support regulatory and client inspections and provide guidance on responses, including root cause and CAPA plans as applicable.
  • Author Major deviations, Change Controls and CAPAs as required on behalf of Quality Assurance.
  • Attend daily meetings such as Manager Work Center Team (WCT), Deviation triage, etc. on behalf of Quality Assurance.
  • Work cross-functionally with other departments for metrics reviews, operational support and quality system management.
  • Identify and drive continuous improvement opportunities throughout the organization utilizing LEAN ideologies.
  • Partner with stakeholders throughout the organization to drive quality mindset and culture.
  • Performs other related QA duties as assigned including but not limited to supporting QA on the floor.

Abzena is a CDMO that provides integrated services for complex biologics and bioconjugates, including antibody-drug conjugates (ADCs). It supports projects from antibody discovery through GMP manufacturing for clinical trials and commercial supply, using its in-house platforms and expertise. It differentiates itself with end-to-end development and manufacturing capabilities, supported by proprietary technologies like ThioBridge and Composite Human Antibody, and global facilities in San Diego, Bristol, and Cambridge. Its goal is to help biologics programs progress efficiently from discovery to market by offering specialized, partnered development and manufacturing services and potential licensing of its technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Babraham, United Kingdom

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • Geoffrey M. Glass appointed CEO July 22, 2025, drives growth.
  • Dr. Moncef Slaoui joins board January 8, 2025, boosts innovation.
  • Scientific Advisory Board formed May 15, 2025, guides ADC strategies.

What critics are saying

  • Lonza acquires Halo Life Science March 17, 2026, steals ADC share.
  • WuXi Biologics launches 10 ADC technologies Q1 2026, undercuts ThioBridge®.
  • FDA warning letter halts Bristol PA trials January 15, 2026.

What makes Abzena unique

  • ThioBridge® platform creates stable, effective ADCs for clients.
  • Composite Human Antibody™ reduces immunogenicity in biologics.
  • AbZelectPRO™ launches GS knockout CHO-K1 for afucosylated proteins.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Abzena who can refer or advise you

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Abzena
Mar 17th, 2026
Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations.

Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations. Abzena is recognized as a technology-forward, innovative CDMO in the Frost radar(tm): ADC contract development and manufacturing report, 2025. In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research analysts Frost & Sullivan, an independent firm, evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth. As the author of the report, Unmesh Lal, VP of Healthcare & Life Sciences at Frost & Sullivan, shared, "With deep analytical expertise, flexible licensing models, and a dual US-UK footprint, Abzena combines scientific rigor with commercial agility. Its 'grow-with-the-client' strategy is converting early-stage partnerships into long-term manufacturing relationships, solidifying its position as a premier end-to-end CDMO for complex biologics." * How Abzena's proprietary ThioBridge(R) site-specific conjugation platform improves the design & delivery of ADCs. * How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs. * How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors * How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.

Clinical Research News
Sep 16th, 2025
Abzena Enhances AbZelectPRO(TM) Cell Line Offering with New GS Knockout Platforms

Abzena enhances abzelectpro(tm) cell line offering with new GS knockout platforms san diego, CA - september 15, 2025 - abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its abzelectpro(tm) cell line development (CLD) platform with the launch of two next-generation glutamine synthetase ("GS") knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Bio-IT World
Jul 22nd, 2025
Appointment; Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

San Diego, CA - July 22, 2025 - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately.

PR Newswire
May 15th, 2025
Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation.Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster."Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth

Abzena
Apr 24th, 2025
Abzena's Customer Archetype Therapeutics to Present at AACR 2025 on Lung Cancer Drug Candidate Results

Archetype is partnering with contract research organizations (CROs) Abzena and Alloy Therapeutics, to design and develop Antibody-drug conjugates (ADCs) using some of the clinical stage and approved targeted therapy small molecules featured in the presentation.